A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.
Shaun D FontaineChristopher W CarrerasRalph R ReidGary W AshleyDaniel V SantiPublished in: Cancer research communications (2023)
A circulating conjugate that slowly releases Exa is described. It is efficacious after a single dose and synergistic with ATR and PARP inhibitors.